Below you'll find a list of all posts that have been tagged as “NMPA”
China has always been an attractive destination for researchers in the healthcare sector because of its size and population, and the scale of studies thus made possible. Until recently, though, its regulatory system was cumbersome and not well designed for foreigners, who found it hard to understand what was required of them. Thankfully, the past couple of years have seen …
If you’ve only recently taken an interest in the healthcare sector in China, you may be confused by some of the acronyms you see floating around, and wonder why there seem to be multiple agencies doing the same jobs. You’ll be pleased to hear that the confusion in some English language publications mainly results from a change of name and …
The last decade has seen increasing emphasis worldwide on the importance of well-regulated, real-world data collection and analysis as a follow-up to clinical trials for new medicines and medical devices. China is now taking steps to make regulatory changes of its own in this area. On 7 January 2020, the National Medical Products Association (NMPA) released a paper entitled Guiding …
